The anti-obesity medication market reached USD 19.84 billion in 2025. The market growth can be attributed to expansion of healthcare infrastructure in highly populated underserved regions, development of advanced combination formulations incorporating multi-incretin activity, and acknowledgment that obesity is a chronic disease by global standards and guidelines. These trends were evaluated by our Senior Research Analyst, Deepa Pandey, to curate this well-researched report. Her analysis benefits pharmaceutical producers, distributors, medical professionals, and stakeholders in performing competitive analysis and taking well-informed decisions.
